When do you start to see weight loss on Wegovy?

What the trial data says about the early weeks

The STEP 1 trial is the clearest window into Wegovy's timeline. Across 68 weeks, participants lost an average of around 15% of their body weight at the standard 2.4mg dose alongside a reduced-calorie diet and increased physical activity. But the trial's weekly data (reviewed closely in the NICE appraisal of semaglutide) shows that weight loss is not a straight line. The steepest decline tends to occur once dose escalation is properly underway, roughly between months two and six. At the starting 0.25mg dose, most people notice appetite shifting before the scales shift noticeably. That early period is less about dramatic weight loss and more about your body adjusting to the medicine.

This is worth sitting with, because impatience at week three is one of the most common things prescribers hear. If you are wondering when you actually see weight loss on Wegovy, the evidence points to a gradual shift rather than an immediate one, with a few hundred grams in the first fortnight not being a signal that the treatment is not working. How long Wegovy takes to work is a question the evidence answers in months, not days.

The dose escalation ladder and why it shapes your timeline

Wegovy's titration schedule exists primarily to reduce gastrointestinal side effects, nausea, diarrhoea, and indigestion are most noticeable at higher doses, and stepping up slowly gives the body time to adapt. The schedule runs 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg, with approximately four weeks at each level. In April 2026 the MHRA also approved a single-dose 7.2mg pen for adults with a BMI of 30 or above, representing a new higher maintenance option for those who tolerate and respond well to semaglutide.

What this means practically: most people do not reach the maintenance dose until around month five. Weight loss at 0.25mg and 0.5mg tends to be modest. It accelerates as doses rise. So if someone tells you they tried Wegovy for six weeks and saw little change, the relevant question is which dose they were on at the time. The full Wegovy treatment overview covers the licensed doses and what to expect at each stage.

Your prescriber controls the titration. Skipping steps to speed things up is not recommended, and responsible clinical services will not approve a dose increase without evidence of how the current dose is being tolerated.

Plateaus, slow weeks and what they actually mean

Most people experience at least one period during Wegovy treatment when the scale stops moving. This is normal and documented. Energy expenditure adapts as body weight falls, the body defends its weight, a biological reality that has nothing to do with effort. The NHS patient information for semaglutide notes that treatment works best alongside dietary changes and increased activity precisely because the medicine addresses appetite regulation, not the full metabolic picture on its own.

A plateau in month four or five does not mean you have reached your limit. For many people, continued dose escalation breaks it. For others, a review of food choices (particularly protein and fibre intake, which tend to suffer when appetite falls sharply) makes the difference. If you are four weeks into a new dose and weight has not moved at all, that is worth raising with your prescriber. It is not, on its own, a reason to stop.

Thinking about the cost of treatment alongside these timelines is reasonable. What Wegovy costs in the UK is a separate question from whether it represents value, and the answer depends partly on how long you are likely to need it and what is included in the price you are quoted.

Who tends to see results sooner, and who takes longer

Individual variation is real. Body weight at baseline, metabolic history, how consistently someone follows the dietary guidance, sleep quality, stress levels and whether conditions like hypothyroidism or polycystic ovary syndrome are also present all influence the timeline. Many people find it helpful to understand when you can realistically start to see results from Wegovy, because the STEP 1 data shows sustained loss well into the second year of treatment for most participants who stayed on the maintenance dose, and a slower start does not predict a poorer outcome overall.

A starting BMI above 40, for example, often means larger absolute losses but a similar percentage trajectory to someone starting at BMI 32. The direction matters more than the week-four number. If you are weighing up when to expect results on Wegovy relative to your own situation, a clinical consultation is the most useful starting point, because the prescriber can account for what a chart of averages cannot.

Our clinical team at nume reviews every consultation the same day. A real prescriber, not an automated system, reads your answers and determines whether Wegovy is clinically appropriate for you. If you are ready to understand your own timeline rather than read about averages, start your free consultation and get a clear picture.